Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Compound 21

Phase 1Small molecule

AAnna Stanhewicz, PhD

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Preeclampsia PostpartumActive, not recruiting

Preeclampsia PostpartumPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Preeclampsia Postpartum

NCT05937841

Clinical

Trials by Indication[1]

Sex Differences1 trial

Sex Differences in the Dilatory Response of Compound 21

Completed·—·Phase 1·NCT05576155·26 enrolled

Preeclampsia1 trial

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

Completed·—·Phase 1·NCT06157580·24 enrolled

Preeclampsia Postpartum1 trial

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Active, not recruiting·AAnna Stanhewicz, PhD·Phase 1·NCT05937841·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Compound 21. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Compound 21 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Compound 21. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anna Stanhewicz, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAnna Stanhewicz, PhD

Related News